Torrent Pharmaceuticals stock (INE482A01020): Q3 profit jumps 27.6% on revenue growth

Torrent Pharmaceuticals reported a 27.6% rise in Q3 FY26 net profit to Rs 642 crore, with revenue up 17.7% to Rs 3,251 crore. Shares rose 0.60% to Rs 4,180.

Torrent Pharmaceuticals released its Q3 FY26 results, showing consolidated net profit increased 27.6% year-over-year to Rs 642 crore, driven by a 17.7% rise in revenue from operations to Rs 3,251 crore compared to Q3 FY25, according to Tickertape as of May 2026. The shares gained 0.60% to Rs 4,180 on the BSE following the announcement.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Torrent Pharmaceuticals Ltd
• Sector/industry: Health Care / Pharmaceuticals
• Headquarters/country: India
• Core markets: India, US, emerging markets
• Key revenue drivers: Branded and generic drugs
• Home exchange/listing venue: BSE/NSE (TORNTPHARM)
• Trading currency: INR

Torrent Pharmaceuticals: core business model

Torrent Pharmaceuticals manufactures and markets branded and generic pharmaceutical products across therapeutic areas including cardiovascular, central nervous system, diabetology and gastro-intestinal. The company operates in over 40 countries with a focus on high-growth emerging markets and the US generics space, according to its official website.

With manufacturing facilities in India approved by major regulators like USFDA, Torrent emphasizes research-driven innovation alongside a strong generics portfolio. Its business model balances high-margin branded drugs in India with volume-driven exports.

Main revenue and product drivers for Torrent Pharmaceuticals

Pharmaceuticals form the core revenue segment, with exports and domestic branded formulations as key drivers. In Q3 FY26 ending December 2025, revenue grew 17.7% to Rs 3,251 crore, reflecting strong demand, per Tickertape as of May 2026. Products like Ranolazine target US markets, supporting Torrent Pharma Inc.'s presence in oncology, dermatology and neurology.

The company's large-cap status with market cap around Rs 1.45 lakh crore underscores its scale in India's pharma sector, which supplies significantly to US drug needs.

Industry trends and competitive position

India's pharma industry benefits from US generics demand, where Torrent holds ambitions via ANDA filings like sacubitril/valsartan, amid patent litigations such as Novartis v. Torrent, per PatSnap. Torrent's P/E of 76.07 and P/B of 19.15 reflect growth premium.

Why Torrent Pharmaceuticals matters for US investors

Torrent Pharmaceuticals offers US investors exposure to India's pharma boom, with Torrent Pharma Inc. marketing drugs like Ranolazine for US prescriptions. Its USFDA-approved plants and export focus tie into American healthcare supply chains, providing diversification beyond domestic US biotech.

Conclusion

Torrent Pharmaceuticals demonstrated solid Q3 FY26 growth with profit up 27.6% and shares ticking higher. Ongoing US market efforts and strong fundamentals position it amid India's pharma export surge. Investors track derivatives activity and technical strength signaling momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.